ACG brings fully integrated OSD manufacturing to Europe at Interpack 2026
Pharmaceutical manufacturing is becoming more demanding. Rising SKU variability, tighter timelines, and growing pressure to deliver more from every investment are pushing manufacturers to rethink their production strategies and to demand more from the partners they rely on.
At Interpack 2026, ACG, the world’s most integrated provider of solid dosage solutions, will demonstrate how integrated, intelligent systems can help manufacturers build better value into their oral solid dosage (OSD) operations, with solutions designed for flexibility, consistency, and long-term performance.
Go BackMedication adherence should be a product design priority.
Medication non-adherence is estimated to raise healthcare costs by $5,000–$52,000 per patient annually in the United States.1 It’s often treated as a patient behaviour problem. But for many elderly adults, it’s also a product design issue.
Regimen complexity, swallowability and packaging design all converge to influence correct administration in real-world use. Product development should therefore evaluate patient usability as early as formulation and packaging design, rather than treating non-adherence as a downstream patient issue.
Medication non-adherence is estimated to raise healthcare costs by $5,000–$52,000 per patient annually in the United States.1 It’s often treated as a patient behaviour problem. But for many elderly adults, it’s also a product design issue.
Regimen complexity, swallowability and packaging design all converge to influence correct administration in real-world use. Product development should therefore evaluate patient usability as early as formulation and packaging design, rather than treating non-adherence as a downstream patient issue.
ACG joins the United Nations Global Compact Network India.
ACG Associated Capsules and ACG Pharmapack are new participants in the UNGC, which supports companies on their journey to align their practices to a sustainable and inclusive future.
Restoring dissolution performance for a first-to-file launch.
A global pharmaceutical company was the first to file an ANDA for a Fexofenadine + Pseudoephedrine extended-release MUPS tablet, with 180 days of market exclusivity.
ACG partners with Allied Pharma to present cartoning machines at Interpack
ACG and Allied Pharma announce plans to present packaging and cartoning machines Blister X and Karton X at Interpack 2026.
Lalit Kasliwal
Serious About Sustainability – and Raising the Bar
Sustainability in pharma can’t sit on the margins. It has to shape how we design...